Treatment Outcomes after Discontinuation of Ethambutol due to Adverse Events in Mycobacterium avium Complex Lung Disease.

Abstract

BACKGROUND:

Long-term administration of ethambutol (EMB) for Mycobacterium avium complex lung disease (MAC-LD) sometimes leads to permanent discontinuation of EMB due to various adverse events. This study aimed to investigate treatment outcomes after discontinuation of EMB.

METHODS:

Among patients diagnosed with MAC-LD between January 2001 and December 2014, 508 patients whose treatment was initiated with standard regimen until May 2018 were enrolled at a tertiary referral center in Korea. Of these 508 patients, 60 (11.8%) discontinued EMB due to various adverse effects. Among these 60 patients, treatment outcomes were analyzed for 44 patients by comparing their outcomes with those of matched subjects who received the standard treatment regimen without EMB discontinuation.

RESULTS:

The mean age of the 60 patients who discontinued EMB was 64.4 years. Ocular toxicity was the most common cause of discontinuation of EMB (75.0%, 45/60). The mean duration of EMB administration before its discontinuation was 7.0 ± 4.6 months. The treatment failure rate of the 44 patients with EMB discontinuation analyzed for treatment outcome was 29.6%, which was higher than that of the matched patients who received the standard regimen (18.3%), although the difference was not significant (P = 0.095). Of these 44 patients, EMB was substituted with later-generation fluoroquinolone in 23 patients, and the treatment failure rate of these 23 patients was significantly higher than that of the matched patients who received the standard regimen (39.1% vs. 19.3%, P = 0.045).

CONCLUSION:

These findings suggest that treatment outcomes are unsatisfactory in patients with MAC-LD who discontinue EMB owing to adverse events. Notably, there was a statistically significant high failure rate in patients who were prescribed fluoroquinolone to replace EMB.

• Authors: Yong Shik Kwon, Byoung Soo Kwon, Ock Hwa Kim, Yea Eun Park, Tae Sun Shim, Yong Pil Chong, Kyung Wook Jo
• Journal: Journal of Korean medical science (J Korean Med Sci) Vol. 35 Issue 9 Pg. e59 (Mar 09 2020) ISSN: 1598-6357 [Electronic] Korea (South)
• PMID: 32141249 (Publication Type: Journal Article)
• Copyright: © 2020 The Korean Academy of Medical Sciences.

Chemical References

• Antitubercular Agents
• Fluoroquinolones
• Ethambutol

Topics

• Aged
• Antitubercular Agents (adverse effects, therapeutic use)
• Ethambutol (adverse effects, therapeutic use)
• Female
• Fluoroquinolones (therapeutic use)
• Humans
• Lung Diseases (diagnosis, drug therapy, microbiology)
• Male
• Middle Aged
• Mycobacterium avium Complex (isolation & purification)
• Mycobacterium avium-intracellulare Infection (diagnosis, drug therapy, microbiology)
• Republic of Korea
• Retrospective Studies
• Tertiary Care Centers
• Treatment Outcome